Arrowhead Pharmaceuticals (ARWR) Common Equity (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Common Equity data on file, last reported at $614.0 million in Q1 2026.

• Quarterly Common Equity fell 10.27% year-over-year to $614.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $614.0 million (down 10.27% YoY) and the FY2025 annual result came in at $466.1 million, up 143.93% from the prior year.
• Common Equity grew to $614.0 million in Q1 2026, from $562.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $684.2 million in Q1 2025 to a low of $56.1 million in Q4 2024.
• A 5-year average of $410.6 million and a median of $452.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity tumbled 67.72% — and 2025, when it soared 903.47%.
• Tracing ARWR's Common Equity over 5 years: stood at $396.4 million in 2022, then sank by 56.17% to $173.7 million in 2023, then plunged by 67.72% to $56.1 million in 2024, then soared by 903.47% to $562.7 million in 2025, then advanced by 9.11% to $614.0 million in 2026.
• The last three Common Equity figures came in at $614.0 million (Q1 2026), $562.7 million (Q4 2025), and $466.1 million (Q3 2025), per Business Quant data.